Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bioresus is an Australian biotechnology company focused on developing innovative resuscitation and organ preservation therapies. The company's core technology, the ALM (Adenosine, Lidocaine, and Magnesium) solution, is designed to stabilize patients during critical care scenarios such as hemorrhagic shock, sepsis, and traumatic brain injury. By modulating the body's response to extreme stress and inflammation, Bioresus aims to extend the golden hour for trauma victims and improve outcomes in emergency medicine. Their pipeline includes applications for both military and civilian trauma care, as well as solutions for extending the viability of donor organs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bioresus.